Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.46 |
| ▸ | THRA | P10827 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455399 | 0.86 | MEN1 (0.49) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL7138795 | 0.79 | MEN1 (0.46) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL5760588 | 0.78 | MEN1 (0.55) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL6455630 | 0.75 | MEN1 (0.45) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL10667190 | 0.75 | MEN1 (0.55) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL9166052 | 0.73 | MEN1 (0.54) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL6343976 | 0.73 | MEN1 (0.50) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL11460749 | 0.72 | MEN1 (0.51) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL7919792 | 0.72 | MEN1 (0.56) | THRBTHRAMEN1NR1I2KMT2A | |
| SCHEMBL5565457 | 0.72 | MEN1 (0.42) | THRBTHRAMEN1NR1I2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN CILAG S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | ALOX5, IL5, IL6ST | THRB 1610/4885THRA 1581/4885MEN1 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.